Royal Foundation NHS Trust, Manchester , UK FTLD than in controls. Additionally, AD had higher microglial activation in the CA1 and FTLD in the hippocampal white matter than the controls. Microglial activation was greater in the dentate gyrus molecular layer in AD than in FTLD. In the cortical regions, the 2 pathological groups differed only in frontal white matter, with the FTLD group showing higher microglial scores. FTLD showed higher microglial activation in the white matter compared to the respective gray matter in the entorhinal, temporal, and frontal regions. Conclusions: Our work expands the knowledge of the distribution and magnitude of microglial activation in these disorders. Additionally, we found some microglial circuit-specific patterns that could help to explain some of the clinical overlap between AD and FTLD-TDP, namely in memory deficits.
Introduction
Microglial cells are the predominant resident immune cells of the central nervous system and are considered as tissue-resident macrophages. The functions of microglia in the normal healthy brain beyond immune surveillance are unclear, but, recently, more sophisticated functions such as participating actively in the protection and remodeling of synapses were described [1, 2] . In addition, microglial activation occurs early in the pathogenesis of neurodegenerative diseases [3, 4] .
Alzheimer disease (AD) is the most common cause of dementia worldwide, followed by frontotemporal lobar degeneration (FTLD) in people younger than 65 years of age [5] . Both AD and FTLD are characterized by the accumulation and aggregation of misfolded proteins. Whereas AD pathology is characterized by extracellular amyloid beta (Aβ) plaques and intracellular aggregates of aberrantly phosphorylated tau protein, i.e., neurofibrillary tangles (NFT), the pathology of FTLD is more heterogeneous. Approximately half of the cases are defined by the presence of tau-immunoreactive changes (NFTlike structures, Pick bodies, or glial inclusions) [6] , and have been designated as FTLD-tau [7] . Most of the remaining cases of FTLD are associated with the presence of various combinations of immunoreactive TDP43 neuronal cytoplasmatic inclusions, dystrophic neurites, and neuronal intranuclear inclusions [6] , and such cases have been designated as FTLD-TDP [7] . It is believed that the abnormal protein accumulation can trigger a brain inflammatory reaction, inducing the production of a series of proinflammatory mediators and microglial activation [8, 9] .
Cumulative data suggest that neuroinflammation plays a prominent and early role in AD [8] . Neuropathological studies have shown the presence of a broad variety of inflammation-related proteins (complement factors, acute-phase proteins, and proinflammatory cytokines) and clusters of activated microglia around amyloid plaques in AD subjects [10] . In vivo imaging studies, using the 11-C-R-PK1195 PET ligand, showed that activated microglia accumulate near the amyloid plaque pathology, and that activated microglia burden correlates with cognitive decline in AD [11] . Using the same ligand, in a small cohort of FTLD patients, activated microglia were detected in the typically affected frontotemporal brain regions [12] . Recently, Lant et al. [13] , in a postmortem immunohistochemistry (IHC) study, showed higher levels of microglial activation in the frontal and temporal cortices, and the white matter of FTLD patients.
Previous neuropathological studies were focused on individual neurodegenerative disorders and limited brain regions, and so they did not address possible regional differences in microglial activation within the central nervous system or pathologies. Taking into account the microglia-driven neuroinflammation role in the pathophysiology of neurodegenerative disorders, we sought to extend previous studies, regarding the characterization of the distribution of microglial cell activation in these 2 neurodegenerative dementias. We selected the TDP43 pathological subtype of FTLD to compare 2 distinct "proteinopathies." TDP43 pathology was found to be present in AD [14] and it has been shown to be associated with typical AD characteristics such as episodic memory loss and hippocampal atrophy [15] . Furthermore, the FTLD-TDP subtype has been associated with more severe episodic memory, and hippocampal atrophy may be a potential biomarker for FTLD-TDP in vivo [16] . AD cases with TDP43 pathology were excluded from the analysis.
Patient and Methods

Patients
Forty-six cases were investigated. The majority were obtained from the Manchester Brain Bank (15 AD, 10 FTLD, and 4 controls) through appropriate consent procedures for the collection and use of human brain tissues. Additionally, 14 control cases were obtained from the Oxford Brain Bank and 3 FTLD cases were obtained from the Portuguese Brain Bank, also through appropriate consent procedures for the collection and use of human brain tissues. Cases were approximately age-matched. The AD cases met the pathological criteria for definite AD ("high" AD neuropathologic change) [17] . Cases with associated hippocampal sclerosis and/or TDP43 pathology were excluded. The FTLD cases met the pathological criteria for FTLD [18] and all cases were FTLD-TDP (11 FTLD-TDP type A, 1 type B, and 1 type C) [7] . The 18 controls were judged to be clinically normal and none showed any pathology beyond that which might be anticipated for their age.
Methods
Immunohistochemistry
The IHC staining for CD68 was performed using the Ventana OptiView DAB IHC detection kit and BenchMark Ultra processor (Ventana, Tucson, AZ, USA). Sections of the temporal (including hippocampus and parahippocampal region), frontal, parietal, and occipital cortices were cut at 6-μm thickness from formalin-fixed, paraffin-embedded blocks and mounted on to glass slides. Paraffin tissue sections were deparaffinized with EZ Prep (Ventana) at 75 ° C for 16 min and pretreated with heat treatment with Ultra Cell Conditioning Solution (CC1, Ventana), and then the endogenous peroxidase was inactivated before incubation with the CD68 antibody (PG-M1, 1: 400, Dako, Glostrup, Denmark) for 24 min at 36 ° C. Subsequently, the slides were incubated with OptiView HQ linker for 8 min, and with OptiView universal HRP multimer (Ventana) for 8 min at 36 ° C. Tissue sections were incubated with OptiView universal DAB chromogen (Ventana) for 8 min to detect the antigen-antibody complex and then counterstained with hematoxylin II (Ventana).
Similar study methods for IHC were used with Iba1 antibody (Wako cat. No. 019-19741) in a random series of frontal sections from across the groups (15 cases).
Microscopic Analysis
The CD68 and Iba1 antibodies mark microglial cells, both in a resting and activated condition ( Fig. 1 ) . Sections of the different regions of interest were assessed for the presence of immunostained microglial cells within both the cortical gray matter and the subcortical white matter at ×20 magnification. As previously described [13] , the frequency and "severity" (in terms of morphological types, with activated microglial cells being considered to be more severe than ramified microglial cells) of CD68-immunostained sections were assessed according to the following criteria: 0 = no immunostained cells present; 1 = very few immunostained cells present, all as ramified microglia; 2 = a moderate number of immunostained cells present, mostly ramified but some activated cells present; 3 = many, diffusely spread, immunostained cells present, all as activated microglia; 4 = many, large clusters of activated microglial cells present ( Fig. 2 ) . The perivascular CD68-immunostained cells (perivascular macrophages) were not considered for the score analysis.
In each section, scores were given for the cortex and the white matter. Additionally, in the temporal block, scores were given for hippocampal formation (CA1, CA2/3, the dentate gyrus [DG] granular cell layer, the DG molecular layer [DG-ML], and the subiculum), the hippocampal white matter, the entorhinal cortex, and the entorhinal white matter.
The assessment of Iba1 scores followed the same methods as for CD68.
All assessments were made by a single observer (R.T.), who was blinded to diagnosis. Sections were scored twice to increase objectivity, and discrepancies were reconciled by consultation with a second observer (M.M.P.). In addition, a random set of 8 sections was scored on a weekly basis over the course of the study.
Statistical Analysis
Rating data were entered into an Excel spreadsheet and analyzed using SPSS software v22.0. A p value <0.05 was considered statistically significant. The Kruskal-Wallis test was performed for analysis. If this detected any significant differences between the groups, post hoc testing was performed to identify the groups between which significant differences existed (by pairwise comparison). The Friedman two-way analysis and the Wilcoxon signedrank test were used to compare different areas within each group.
Results
Three groups were established ( Table 1 ) based on confirmation from pathology; cases were grouped as AD ( n = 15), FTLD ( n = 13) and nondemented controls ( n = 18). There were no differences between AD, FTLD, and controls in age at death. The AD and FTLD groups do not differ in age at onset or disease duration ( p > 0.05) (online suppl. Table 1 ; for all online suppl. material, see www. karger.com/doi/10.1159/000457127).
Histological Analysis
Resting microglia are characterized by a small cell body and ramified processes with a weak expression of associated cell surface marker antigens [19] . This "ramified" microglial cell phenotype is seen when no apparent tissue pathology is present ( Fig. 1 a) . In response to injury or disease, microglia change into a macrophage-like phenotype ( Fig. 1 b) , displaying shortened processes and hypertrophy of the cell body [3] .
As previously described [13] , the topographic distribution of activated microglial cells generally followed that of the principal pathological changes within the cortex and hippocampal formation. In the AD group, activated microglial cells were often clustered within and around amyloid plaques. The number of morphologically activated microglial cells was also high in the subcortical white matter, with a more dispersed distribution. In the FTLD group, activated microglial cells were more evident in the upper (I-III) than in the lower (IV-VI) cortical layers, and more so in the subcortical white matter than in the cortical gray matter (particularly in the entorhinal, temporal, and frontal areas).
In the controls, activated microglial cells were largely absent in most of the cases, though a few were occasionally seen in association with rare amyloid deposits. Ramified microglial cells were commonly seen in many of these cases. The morphological patterns were similar with both antibodies, with Iba1 showing a better definition of the ramified morphology of the resting microglia (online suppl. Fig. 1 ). In the sections analyzed with both antibodies, microglial scores showed a good correlation between them ( r = 0.609, p < 0.01 in frontal cortex; r = 0.514, p < 0.05 in frontal subcortical white matter, the Kendall τ coefficient; online suppl. Fig. 2 ). The CD68 antibody was used as the principal microglial marker in the study for better comparison with the original study of the group [13] . Representative examples of the microglial assessment according to the scale description. CD68.
Color version available online
Microglial Scores Based on the Patterns of CD68 Staining Hippocampal Formation Microglial cell scores were significantly different across the AD, FTLD, and control groups for the CA1 region of the hippocampus ( p = 0.037), the DG-ML ( p = 0.016), the subiculum ( p = 0.002), and the hippocampal white matter ( p = 0.016). Pairwise comparisons showed that the AD group had higher microglial scores than the control group in CA1 ( p = 0.031) and subiculum ( p = 0.005). The FTLD group had higher microglial scores than the control group in the subiculum ( p = 0.022) and hippocampal white matter ( p = 0.014), and, interestingly, lower microglial scores in the DG-ML ( p = 0.043). The scores of the 2 pathological groups (AD and FTLD) differed only in the DG-ML, with the AD group showing higher microglial scores ( p = 0.026) ( Fig. 3 ).
Cortex and Subcortical White Matter Microglial cell scores were significantly different in the AD, FTLD, and control groups for the entorhinal cortex and white matter ( p = 0.036 for both), the temporal cortex ( p = 0.007), and the frontal cortex and white matter ( p = 0.047 and p = 0.007, respectively). There was no significant effect of disease status in the other regions studied (temporal white matter, parietal cortex and white matter, occipital cortex and white matter).
Pairwise comparisons showed that the AD group had higher microglial scores than the control group in the entorhinal cortex ( p = 0.030) and temporal cortex ( p = 0.007). The entorhinal white matter showed a trend ( p = 0.053) of higher values in the AD cases. The FTLD group had higher microglial scores than the control group in the frontal white matter ( p = 0.012) and a trend in the frontal cortex ( p = 0.053). The 2 pathological groups (AD and FTLD) differed only in the frontal white matter, with the FTLD group showing higher microglial scores ( p = 0.025).
Microglial Cell Activation in the Cortical and Subcortical Areas
To assess the distribution of microglial cell activation in each group, the Wilcoxon signed-rank test was used. In the AD group, there were no differences when comparing the microglial scores in the cortical and subcortical white matter in each region ( p > 0.05). In the FTLD group, the entorhinal, temporal, and frontal regions had significantly higher microglial scores in the white matter compared to their respective gray matter ( p = 0.020, p = 0.003, Comparison of microglia scores between gray matter and white matter within groups in different regions. Ec, entorhinal cortex; Ewm, entorhinal white matter; Tc, temporal cortex; Twm, temporal white matter; Fc, frontal cortex; Fwm, frontal white matter; Pc, parietal cortex; Pwm, parietal white matter; Oc, occipital cortex; Owm, occipital white matter. Bars represent ± SE. * p < 0.05; * * p < 0.01.
and p = 0.021, respectively). As expected, in the control group, the test showed that all cortical areas had lower microglial scores when compared to their subcortical white matter ( p = 0.011 for the entorhinal, temporal, and parietal areas; p = 0.001 in frontal area and p = 0.003 in occipital area) ( Fig. 4 ) .
Correlations between Microglial Cell Activation and Age at Onset, Age at Death, and Disease Duration
In the AD group, there was a positive correlation between both age at onset and age at death and the occipital cortex microglial scores ( r = 0.590, p = 0.021, and r = 0.570, p = 0.027, respectively). For the occipital white matter, there was a positive correlation only with age at death ( r = 0.603, p = 0.017). There were no correlations in any of the other areas studied or with the years of disease duration.
In the FTLD group, there were no correlations between any of the 3 variables and the microglial cell activation scores.
In the control group, there were no correlations between age at death and microglial scores in any region.
Discussion
This study underscores the differences in severity and distribution of activated microglial cells in 2 neurodegenerative dementias with distinct misfolded protein signatures. We assessed and compared levels of microglial cell activation in 3 groups (cases of AD and FTLD-TDP and controls) in several cortical and subcortical white matter areas (entorhinal, temporal, frontal, parietal, and occipital), and also hippocampal formation.
In the hippocampal region, we found higher microglial scores in the CA1 and subiculum in the AD group than in controls. This is not surprising, given that the CA1 and the subiculum region of the hippocampus are the areas the most affected by neuronal loss in AD [20] ; they are also associated with a higher burden of Aβ plaques and NFT [21] . Postmortem studies on AD brains and in AD mouse models also show the increase of activated microglial cells in these areas [22] [23] [24] [25] . Furthermore, it is known that the density of NFT correlates with that of activated microglia in the subiculum but not in other hippocampal areas [26] . Although microglial activation is a known feature of FTLD pathology [9, 13] , the detailed histopathological study of the different hippocampal areas has not been done before.
In this study, we found that the FTLD group showed higher microglial scores than the control group in the subiculum, but not in the CA1 area. Additionally, there was significantly higher microglial activation in the hippocampal white matter in the FTLD than in the control group.
We excluded AD patients with concomitant hippocampal TDP43 pathology, in order to avoid difficulties in the interpretation of the results. Episodic memory deficits are a well-established early feature of AD [27] , and there is a widely documented relationship between hippocampal impairment and early episodic memory deficits in AD [28] . Moreover, CA1 pathology (neuron loss and NFT burden) correlates with the memory deficits [29, 30] . Interestingly, some studies have demonstrated that patients with a behavioral variant of FTD can present with severe episodic memory [6, 31] , and pathological studies have shown atrophy of the hippocampus [14, 18, 32] and other structures of the Papez circuit [33] on the FTLD spectrum. Additionally, in vivo imaging studies have shown that behavioral-variant FTD cases are associated with more extensive white matter degradation than in AD [34, 35] . Our study supports the contribution of extrahippocampal structures for the episodic memory deficits found in FTLD-TDP patients, i.e., within the connection pathways, as we found prominent microglial activation in the hippocampal white matter (alveolus) without CA1 involvement. This microglial activation is likely to reflect the response to a transsynaptic or transaxonal retrograde cortical degeneration. Moreover, the higher microglia scores found in the DG-ML of the AD group versus in the FTLD group emphasize the contribution of Aβ pathology to the local neuroinflammatory process driven by the microglia. Surprisingly, the control group showed higher microglial scores in this region than the FTLD group; although this finding is difficult to explain (and it is probably related to some Aβ deposits found in the control group), it reinforces the absence of microglial reaction in the DG of the FTLD-TDP cases (despite the known dentate fascia TDP43 inclusions in this pathology).
When addressing the cortex and subcortical white matter regions, and as would be expected, we found higher levels of microglial cell activation in the AD group than in controls in the entorhinal and temporal cortices, 2 key regions affected by AD pathology. In contrast to Lant et al. [13] , we did not find differences in the temporal subcortical white matter or the frontal cortex. The differences in the age at death, particularly in the control group (younger and with a wider age range in Lant et al. [13] ) in these studies can partially explain this discrepancy. There are compelling data that microglia shift towards a proinflammatory state with aging [36] . Previous studies have showed that the density of ferritin-stained microglial cells were higher in nondemented elderly control subjects than in young controls in the entorhinal cortex and all areas of the hippocampal formation [26] . Taking this into account, the magnitude of the differences found in the quantification of microglial cell activation, at least using the methods of this study, can be attenuated with increasing aging due to the age-related changes in microglia.
The frontal subcortical white matter in the FTLD group was different from that in the control group, and there was trend of higher microglial activation in the frontal cortex of the FTLD group. Lant et al. [13] also described higher microglial activation scores in the frontal and temporal cortices and the associated subcortical white matter compared to controls. They showed that FTLD-tau have more microglial activation cells in the temporal region (cortical and particularly subcortical white matter) than FTLD-TDP [13] . In our study, we analyzed only the FTLD-TDP subtype, and our results reinforce their finding of a less microglial pathology in its temporal regions. As expected, there were no differences in the other cortical areas analyzed, in agreement with the selective anatomical involvement that characterizes most FTLD cases [37] . Interestingly, when comparing the 2 pathological groups (AD and FTLD), we found the same differences in subcortical frontal gray matter as Lant et al. [13] found in these 2 groups, and the FTLD group showed higher microglial scores, but not in temporal cortex (although there was a trend for higher microglial scores in the AD group). The smaller number FTLD cases in our sample may also have contributed to some of the discrepancies between these 2 studies. However, our findings support the importance of neuroinflammation in neurodegenerative disease, particularly the more pronounced microglial activation in the frontal subcortical white matter in FTLD-TDP and the more prominent involvement of temporal regions in AD. This pattern likely reflects the distribution of the pathology signature of both conditions. In AD, there is a recognized association between microglial cells and amyloid plaques, leading to a higher cortical gray matter-activated microglia burden in this group [38] . In FTLD-TDP, our findings possibly reflect the direct involvement of TDP43 glial cytoplasmic inclusions usually seen in cerebral white matter, or, and more likely, a microglial cell activation response to a transsynaptic or transaxonal retrograde cortical degeneration. The latter concept is supported by the correlation between the extent of microglial activation and neuronal loss but no correlation with TDP-43 pathology, the finding of a pathological autopsy study of patients with amyotrophic lateral sclerosis with and without dementia [39] .
Interestingly, regional analysis showed the prominent involvement of the white matter rather than the regional cortical gray matter in the FTLD group, namely, in the entorhinal, temporal, and frontal regions. In the AD group, despite there being more frequent clusters of activated microglia surrounding the amyloid plaques in the cortical gray matter, there were no differences when this was compared the subcortical regional white matter. These findings reflect the presence of a more diffuse microglial activation pathology in end-stage AD brains, and reinforce the imaging studies that showed more extensive white matter degradation in the behavioral variant of FTD than in AD [34, 35] . As expected, according to microglia distribution in normal human brains [36] , all cortical areas had lower microglial scores than the regional subcortical white matter in the control group.
The findings reported in this study should be interpreted by taking into account the possibility of interindividual variability in the pathology burden of the 2 entities (Aβ deposition, tau, and TDP pathology), and further studies that correlate microglial activation with these pathology markers would be helpful. For instances, a recent study reported that microglial cells in the hippocampi of severely affected Braak stage V-VI samples were no longer even associated with neuritic plaques or with the vascular amyloid, highlighting the range of microglial alterations [40] .
Despite the relatively small age range of the patients in this study, we found a positive correlation between age and microglial activation scores in the occipital cortex of the AD group. This should be further analyzed in a bigger sample with a greater age range, but it does highlight the possibility of the age-modifying effect in microglia reactions in AD. Vascular pathology was not significant in either of the groups (there was minor small-vessel disease in 1 AD case and 1 control case), so this does not explain differences.
In conclusion, our work extends the knowledge of the distribution and magnitude of microglial activation in these 2 conditions, and describes some microglial circuitspecific patterns that can help to explain the clinical overlap between AD and FTLD-TDP, namely, in memory deficits.
